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BACKGROUND
Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has 
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) 
that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizo-
tinib, in patients with advanced ALK-positive NSCLC who have not previously re-
ceived an ALK inhibitor is unclear.
METHODS
In an open-label, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with 
advanced ALK-positive NSCLC who had not previously received ALK inhibitors to 
receive brigatinib at a dose of 180 mg once daily (with a 7-day lead-in period at 
90 mg) or crizotinib at a dose of 250 mg twice daily. The primary end point was 
progression-free survival as assessed by blinded independent central review. Sec-
ondary end points included the objective response rate and intracranial response. 
The first interim analysis was planned when approximately 50% of 198 expected 
events of disease progression or death had occurred.
RESULTS
A total of 275 patients underwent randomization; 137 were assigned to brigatinib 
and 138 to crizotinib. At the first interim analysis (99 events), the median follow-
up was 11.0 months in the brigatinib group and 9.3 months in the crizotinib 
group. The rate of progression-free survival was higher with brigatinib than with 
crizotinib (estimated 12-month progression-free survival, 67% [95% confidence 
interval {CI}, 56 to 75] vs. 43% [95% CI, 32 to 53]; hazard ratio for disease progres-
sion or death, 0.49 [95% CI, 0.33 to 0.74]; P<0.001 by the log-rank test). The con-
firmed objective response rate was 71% (95% CI, 62 to 78) with brigatinib and 60% 
(95% CI, 51 to 68) with crizotinib; the confirmed rate of intracranial response 
among patients with measurable lesions was 78% (95% CI, 52 to 94) and 29% 
(95% CI, 11 to 52), respectively. No new safety concerns were noted.
CONCLUSIONS
Among patients with ALK-positive NSCLC who had not previously received an ALK 
inhibitor, progression-free survival was significantly longer among patients who 
received brigatinib than among those who received crizotinib. (Funded by Ariad 
Pharmaceuticals; ALTA-1L ClinicalTrials.gov number, NCT02737501.)
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Rearrangements of the oncogenic anaplastic lymphoma kinase (ALK) gene occur in 3 to 5% of patients with non–
small-cell lung cancer (NSCLC).1-3 A previous 
phase 3 trial showed that progression-free sur-
vival was significantly longer among patients who 
received crizotinib, a first-generation ALK inhibi-
tor, than among those who received platinum-
based, double-agent chemotherapy (median pro-
gression-free survival, 10.9 months vs. 7.0 months).4 
Disease progression in the central nervous sys-
tem (CNS) in patients receiving crizotinib is 
common, probably because of its poor brain 
penetration.5-7 Progression beyond the CNS in 
patients receiving crizotinib and other ALK in-
hibitors can occur through the emergence of 
ALK mutations, which are detectable in 20% of 
patients who have received crizotinib and in 56% 
of patients who have received next-generation 
inhibitors. Progression also occurs in patients 
through other mechanisms that are not related 
to ALK mutations.8-10
Brigatinib (Ariad Pharmaceuticals) is a next-
generation ALK inhibitor that targets a broad 
range of ALK mutations and ROS1 rearrange-
ments. It is also the only ALK inhibitor with 
activity in cell lines with mutations in the gene 
encoding epidermal growth factor receptor 
(EGFR).11-14 Step-up dosing of brigatinib over a 
period of 7 days is used to abrogate the risk of 
uncommon early-onset pulmonary events.13 In 
the ALK in Lung Cancer Trial of AP26113 (ALTA) 
involving 222 patients with disease that was re-
fractory to crizotinib, brigatinib administered at 
the recommended dosing regimen of 180 mg 
once daily (with a 7-day lead-in period at 90 mg 
in 110 patients) was associated with high sys-
temic and CNS response rates and a median 
progression-free survival of 16.7 months.15-18 The 
same regimen was associated with similar pro-
gression-free survival (16.3 months) among pa-
tients who had received crizotinib in the phase 
1–2 trial.13,15,19 These median rates of progres-
sion-free survival are higher than those associ-
ated with other next-generation ALK inhibitors 
(including alectinib, ceritinib, ensartinib, and 
lorlatinib) among such patients.17,19-24
The ALK in Lung Cancer Trial of Brigatinib in 
1st Line (ALTA-1L) is a phase 3 trial comparing 
the efficacy and safety of brigatinib with those 
of crizotinib in patients with ALK-positive NSCLC 
who had not received previous treatment with an 
ALK inhibitor. Here we report the results of the 
first prespecified interim analysis.
Me thods
Patients
Eligible patients were at least 18 years of age, 
had locally advanced or metastatic NSCLC with 
at least one measurable lesion according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1,25 and had not previously 
received ALK-targeted therapy. Patients with 
asymptomatic, untreated CNS metastases were 
not excluded. Patients were eligible for trial entry 
on the basis of locally determined ALK testing. 
Patients were excluded if they had previously re-
ceived more than one systemic anticancer ther-
apy regimen for advanced disease or chemother-
apy or radiation therapy (other than stereotactic 
radiosurgery or stereotactic body radiation ther-
apy) within 14 days before the first dose of the 
trial drug. Complete inclusion and exclusion 
criteria are provided in the trial protocol, avail-
able with the full text of this article at NEJM.org.
Trial Oversight
This trial was conducted in accordance with the 
ethical standards of the Declaration of Helsinki 
and the International Council for Harmonisation 
guidelines for Good Clinical Practice. All patients 
provided written informed consent. The protocol 
and informed-consent documents were approved 
by the local institutional review board or ethics 
committee at each site. The trial was designed by 
the sponsor, Ariad Pharmaceuticals, in collabora-
tion with the first author. Data were collected 
and trial procedures were overseen by the trial 
investigators (listed in the Supplementary Ap-
pendix, available at NEJM.org). The sponsor 
analyzed the data, and all the authors had full 
access to the data and participated in the inter-
pretation of the data. The manuscript was writ-
ten by the authors with medical writing assis-
tance paid for by the sponsor. All the authors 
vouch for the completeness and accuracy of the 
data reported and for the adherence of the trial 
to the protocol and statistical analysis plan.
Trial Design
ALTA-1L is an open-label, multicenter, random-
ized, international, phase 3 trial conducted at 124 
centers in 20 countries. Patients were stratified 
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according to baseline brain metastases (present 
or absent) and completion of at least one full cycle 
of previous chemotherapy for locally advanced or 
metastatic disease (yes or no). They were ran-
domly assigned (in a 1:1 ratio) to receive oral 
brigatinib at a dose of 180 mg once daily after a 
7-day lead-in period of 90 mg once daily or oral 
crizotinib at a dose of 250 mg twice daily.
Patients continued treatment until they had 
progressive disease as assessed by an indepen-
dent review committee whose members were 
unaware of the trial-drug assignments, had un-
acceptable toxic effects, or had another discon-
tinuation criterion. In the crizotinib group, cross-
over to brigatinib was permitted after progression 
assessed by means of blinded independent re-
view (with a 10-day washout period from crizo-
tinib). At the investigator’s discretion, treatment 
in the brigatinib group could be continued after 
disease progression. Dose interruptions or reduc-
tions were permitted for treatment-related adverse 
events. Adverse events were categorized with the 
use of the National Cancer Institute Common Ter-
minology Criteria for Adverse Events, version 4.0.
Disease assessment (according to RECIST, 
version 1.1) included imaging of the chest and 
abdomen with the use of computed tomography 
or magnetic resonance imaging (MRI) with con-
trast material and imaging of the head with the 
use of MRI with contrast material. Assessment 
was performed at screening, every 8 weeks 
through cycle 14 (28 days per cycle), and then 
every 12 weeks until the end of treatment. Two 
independent review committees whose members 
were unaware of the trial-drug assignments per-
formed disease assessments: one for all disease 
according to RECIST, version 1.1,25 and one ex-
clusively for the evaluation of intracranial CNS 
end points. Responses were confirmed at least 
4 weeks after the initial response.
Outcomes
The primary end point was progression-free sur-
vival as assessed by blinded independent review 
according to RECIST, version 1.1. Secondary end 
points included the objective response rate and 
intracranial response. A complete list of second-
ary end points is provided in the trial protocol.
Statistical Analysis
Interim analyses were planned after approxi-
mately 50% (99 events) and 75% (149 events) of 
all 198 expected events (disease progression or 
death) were observed. A Lan–DeMets alpha spend-
ing function with O’Brien–Fleming boundaries26 
was used to control the overall alpha level at 0.05 
(two-sided). Assuming an estimated median 
progression-free survival of 10 months among 
patients who received crizotinib in sample-size 
calculations,4 a total of 198 events (disease pro-
gression or death among approximately 270 pa-
tients who underwent randomization) was re-
quired for the trial to have approximately 90% 
power at the final analysis of the primary end 
point to detect a 6-month increase in progression-
free survival (hazard ratio for disease progres-
sion or death, 0.625).
For the first interim analysis, the primary end 
point of progression-free survival was tested at 
a two-sided alpha level of 0.0031. Efficacy was 
evaluated in the intention-to treat population. 
Patients who received at least one dose of a trial 
drug constituted the safety population. For time-
to-event efficacy analyses, median values and 
two-sided 95% confidence intervals were esti-
mated with the use of Kaplan–Meier methods. 
The primary end point was compared between 
the brigatinib and crizotinib groups with the use 
of a two-sided log-rank test stratified according 
to the presence or absence of baseline brain 
metastases and the use or nonuse of previous 
chemotherapy in patients with locally advanced 
or metastatic disease.
Efficacy and safety data are reported as of 
February 19, 2018. Statistical analyses were per-
formed with the use of Base 9.4 SAS/STAT soft-
ware, version 13.1. Statistical methods are de-
scribed further in the statistical analysis plan 
and in the Supplementary Methods section in 
the Supplementary Appendix.
R esult s
Patients
Between April 2016 and August 2017, a total of 
275 patients were enrolled; 137 patients were 
randomly assigned to brigatinib and 138 were 
randomly assigned to crizotinib (Fig. 1). Two 
patients (1 per group) did not receive treatment 
but were included in the intention-to-treat analy-
ses. Baseline factors, including sex, Eastern Coop-
erative Oncology Group performance-status score, 
use of a Food and Drug Administration–approved 
ALK diagnostic test, and the use of previous 
The New England Journal of Medicine 
Downloaded from nejm.org on September 26, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 4
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Figure 1. Screening, Enrollment, Randomization, and Follow-up.
Data reported as of the cutoff date for the first interim analysis (February 19, 2018) are shown. In the brigatinib 
group, 18 patients had documented disease progression according to Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1, and 4 had clinical disease progression. In the crizotinib group, 54 patients had documented 
disease progression according to RECIST, version 1.1, and 7 had clinical disease progression. Crossover from crizo-
tinib to brigatinib was permitted for patients who had objective progression as assessed by blinded independent 
 review. Patients who discontinued crizotinib for other reasons (e.g., progression according to investigator assess-
ments) and then began to receive brigatinib were not included in the number of crossover patients. CNS denotes 
central nervous system.
275 Underwent randomization
311 Patients were assessed for eligibility
36 Were not eligible
4 Were not willing to comply with trial
procedures
3 Had insufficient tumor tissue available
3 Had symptomatic CNS metastases
at screening or asymptomatic disease
leading to an increased dose 
of glucocorticoids within 7 days after
enrollment
26 Did not meet other eligibility criteria
137 Were assigned to receive brigatinib, 180 mg
once daily with a 7-day lead-in at 90 mg
136 Received assigned treatment
1 Did not receive assigned treatment
138 Were assigned to receive crizotinib, 250 mg
twice daily
137 Received assigned treatment
1 Did not receive assigned treatment
137 Were evaluated for primary end point
136 Were evaluated for safety
138 Were evaluated for primary end point
137 Were evaluated for safety
35 Crossed over to brigatinib
Patient status at date of data cutoff:
95 Continued to receive brigatinib
31 Were being followed for survival after
discontinuation of trial treatment
10 Were alive on date of follow-up
10 Died
10 Were not followed for survival after
discontinuation of trial treatment
1 Withdrew consent
Patient status at date of data cutoff:
59 Continued to receive crizotinib
33 Were being followed for survival after
discontinuation of trial treatment
20 Were alive on date of follow-up
10 Died
3 Were not followed for survival after
discontinuation of trial treatment
41 Discontinued treatment
22 Had disease progression
10 Had adverse event
5 Died
2 Were withdrawn from trial by physician
2 Withdrew consent
78 Discontinued treatment
61 Had disease progression
5 Had adverse event
4 Died
5 Were withdrawn from trial by physician
2 Withdrew consent
1 Had other reason
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chemotherapy (and best response to chemo-
therapy) were well balanced between the groups 
(Table 1, and Table S1 in the Supplementary 
Appendix). Of 275 patients, 81 (29%) had brain 
metastases at baseline (29% in the brigatinib 
group and 30% in the crizotinib group), with 
Characteristic Brigatinib (N = 137) Crizotinib (N = 138) Total (N = 275)
Age — yr
Median 58 60 59
Range 27–86 29–89 27–89
Female sex — no. (%) 69 (50) 81 (59) 150 (55)
Race — no. (%)†
Non-Asian 78 (57) 89 (64) 167 (61)
Asian 59 (43) 49 (36) 108 (39)
ECOG performance-status score — no. (%)‡
0 or 1 131 (96) 132 (96) 263 (96)
2 6 (4) 6 (4) 12 (4)
History of tobacco use — no. (%)
Never smoked 84 (61) 75 (54) 159 (58)
Former smoker 49 (36) 56 (41) 105 (38)
Current smoker 4 (3) 7 (5) 11 (4)
Stage of disease at trial entry — no. (%)
IIIB 8 (6) 12 (9) 20 (7)
IV 129 (94) 126 (91) 255 (93)
Histologic type — no. (%)
Adenocarcinoma 126 (92) 137 (99) 263 (96)
Adenosquamous carcinoma 3 (2) 1 (1) 4 (1)
Squamous-cell carcinoma 4 (3) 0 4 (1)
Large-cell carcinoma 2 (1) 0 2 (1)
Other 2 (1) 0 2 (1)
ALK status assessed locally with the use of FDA-approved test — no. %§ 123 (90) 112 (81) 235 (85)
Brain metastases — no. (%)¶ 40 (29) 41 (30) 81 (29)
Previous radiotherapy to brain — no. (%) 18 (13) 19 (14) 37 (13)
Previous chemotherapy in patients with locally advanced  
or metastatic disease — no. (%)‖
36 (26) 37 (27) 73 (27)
*  Percentages may not sum to 100 because of rounding. FDA denotes Food and Drug Administration.
†  Race was reported by the investigator.
‡  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers indicating increasing im-
pairment in activities of daily living.
§  ALK-positive status was confirmed locally by fluorescence in situ hybridization (Vysis) or immunohistochemical assay (Ventana).
¶  The presence of brain metastases was assessed by the investigator.
‖  Previous chemotherapy was defined as completion of at least one full cycle of chemotherapy in patients with locally advanced or metastatic 
disease. Among 36 patients who received previous chemotherapy in the brigatinib group, 2 (6%) had a complete response, 9 (25%) had a 
partial response, 10 (28%) had stable disease, and 8 (22%) had progressive disease; the best response to previous chemotherapy was “oth-
er or unknown” in 7 patients (19%). Among 37 patients who received previous chemotherapy in the crizotinib group, 2 (5%) had a com-
plete response, 8 (22%) had a partial  response, 13 (35%) had stable disease, and 7 (19%) had progressive disease; the best response to 
previous chemotherapy was “other or unknown” in 7 patients (19%).
Table 1. Baseline Patient Characteristics in the Intention-to-Treat Population.*
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similar rates of CNS radiotherapy before en-
rollment.
As of February 19, 2018, a total of 95 patients 
(69%) in the brigatinib group and 59 patients 
(43%) in the crizotinib group continued to re-
ceive trial treatment, with a median follow-up of 
11.0 months (range, 0 to 20.0) and 9.3 months 
(range, 0 to 20.9), respectively. The median dura-
tion of treatment was 9.2 months (range, 0.1 to 
18.4) in the brigatinib group and 7.4 months 
(range, 0.1 to 19.2 months) in the crizotinib 
group. A total of 35 patients who discontinued 
crizotinib because of disease progression crossed 
over to brigatinib treatment as part of the trial 
(see the Supplementary Results section in the 
Supplementary Appendix).
Efficacy
At the first interim data cutoff, a total of 99 
events for the primary end point (disease pro-
gression or death) had occurred in the intention-
to-treat population (36 of 137 patients [26%] in 
the brigatinib group and 63 of 138 patients 
[46%] in the crizotinib group). For blinded inde-
pendent review–assessed progression-free sur-
vival, brigatinib met the prespecified threshold 
for statistical superiority over crizotinib (esti-
mated 12-month progression-free survival, 67% 
[95% confidence interval {CI}, 56 to 75] in the 
brigatinib group and 43% [95% CI, 32 to 53] in 
the crizotinib group; hazard ratio for progres-
sion or death, 0.49 [95% CI, 0.33 to 0.74]; 
P<0.001 by the log-rank test) (Fig. 2A). Accord-
ing to investigator assessment, progression-free 
survival was also longer among patients who re-
ceived brigatinib (estimated 12-month progres-
sion-free survival, 69% [95% CI, 59 to 76] in the 
brigatinib group and 40% [95% CI, 30 to 50] in 
the crizotinib group; hazard ratio for disease 
progression or death, 0.45 [95% CI, 0.30 to 
0.68]). Efficacy consistently favored brigatinib 
across subgroups (Fig. 2B, and Fig. S1 in the 
Supplementary Appendix).
The confirmed objective response rate assessed 
by blinded independent review was 71% (95% CI, 
62 to 78) in the brigatinib group and 60% (95% 
CI, 51 to 68) in the crizotinib group (Table 2). 
The overall objective response rate (objective re-
sponse at one or more assessments, including 
confirmed and unconfirmed responses) was 
76% (95% CI, 68 to 83) in the brigatinib group 
and 73% (95% CI, 65 to 80) in the crizotinib 
group. Changes from baseline in target lesions 
are shown in Figure 2C. The estimated rate of 
the 12-month duration of response in patients 
with a confirmed response was 78% (95% CI, 67 
to 86) in the brigatinib group and 48% (95% CI, 
31 to 63) in the crizotinib group (Fig. S2 in the 
Supplementary Appendix).
Of 275 patients, 90 had brain metastases at 
baseline, as assessed by blinded independent 
review, and 39 had measurable brain metastases 
(≥10 mm in diameter). The confirmed rate of 
intracranial objective response among patients 
with measurable baseline brain metastases was 
78% (95% CI, 52 to 94) (14 of 18 patients) with 
brigatinib and 29% (95% CI, 11 to 52) (6 of 21 
Figure 2 (facing page). Efficacy of Brigatinib  
and Crizotinib in Patients with ALK-Positive NSCLC 
Who Had Not Previously Received an ALK Inhibitor.
Panel A shows Kaplan–Meier estimates of blinded in-
dependent review–assessed progression-free survival 
among patients in the intention-to-treat population.  
Of the 137 patients in the brigatinib group, 36 (26%) 
had an event; of the 138 patients in the crizotinib group, 
63 (46%) had an event. Tick marks indicate censored 
data. NR denotes not reached. Panel B shows hazard 
ratios for disease progression or death across prespec-
ified patient subgroups. The hazard ratio was not calcu-
lated for patients who were current smokers (4 in the 
brigatinib group and 7 in the crizotinib group) because 
of insufficient patient numbers according to the statis-
tical analysis plan. Values for the Eastern Cooperative 
Oncology Group (ECOG) performance-status score  
are on a 5-point scale, with higher numbers reflecting 
greater disability. The hazard ratio was not calculated 
for patients who had an ECOG performance-status 
score of 2 (6 in the brigatinib group and 6 in the crizo-
tinib group) because of insufficient patient numbers 
according to the statistical analysis plan. The presence 
of brain metastases at baseline was assessed by the 
 investigator. The “previous chemotherapy” category  
is previous chemotherapy in patients with locally ad-
vanced or metastatic disease. Panel C shows the best 
percentage change from baseline in the sum of the 
longest diameters of target lesions in patients who 
 underwent follow-up imaging and could be evaluated 
for a response (121 patients in the brigatinib group 
and 122 patients in the crizotinib group). Assessments 
were based on blinded independent review. All trial as-
sessments were used in these calculations. The solid 
line at −30% indicates the threshold for partial response 
according to RECIST, version 1.1. Panel D shows survival 
without intracranial disease progression among patients 
with brain metastases at baseline. Of the 43 patients in 
the brigatinib group, 11 (26%) had an event; of the 47 
patients in the crizotinib group, 28 (60%) had an event. 
Tick marks indicate censored data.
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patients) with crizotinib (Table 2), and the over-
all rate of intracranial objective response (objec-
tive response at one or more assessments, includ-
ing confirmed and unconfirmed responses) in 
this population was 83% (95% CI, 59 to 96) with 
brigatinib and 33% (95% CI, 15 to 57) with 
crizotinib. Overall, 9% (12 of 137 patients) in 
the brigatinib group and 19% (26 of 138 pa-
tients) in the crizotinib group had intracranial 
disease progression as the first site of disease 
Variable Brigatinib Crizotinib Odds Ratio (95% CI)
Intention-to-treat population
No. of patients 137 138
Confirmed objective response
No. of patients 97 83
% (95% CI) 71 (62–78) 60 (51–68) 1.59 (0.96–2.62)
Complete response — no. (%) 5 (4) 7 (5)
Partial response — no. (%) 92 (67) 76 (55)
Rate of objective response at ≥1 assessment — % (95% CI) 76 (68–83) 73 (65–80) 1.13 (0.66–1.97)
Complete response — no. (%) 9 (7) 11 (8)
Partial response — no. (%) 95 (69) 90 (65)
Median duration (95% CI) of confirmed response — mo NR (NR–NR) 11.1 (9.2–NR)
12-mo rate (95% CI) of maintaining response 75 (63–83) 41 (26–54)
Patients with measurable brain metastases at baseline, as assessed 
by blinded independent review†
No. of patients 18 21
Confirmed intracranial objective response
No. of patients 14 6
% (95% CI) 78 (52–94) 29 (11–52) 10.42 (1.90–57.05)
Intracranial complete response — no. (%) 2 (11) 0
Intracranial partial response — no. (%) 12 (67) 6 (29)
Rate of intracranial objective response at ≥1 assessment — % 
(95% CI)
83 (59–96) 33 (15–57) 9.29 (1.88–45.85)
Intracranial complete response — no. (%) 2 (11) 0
Intracranial partial response — no. (%) 13 (72) 7 (33)
Patients with any brain metastases at baseline, as assessed by 
blinded independent review
No. of patients 43 47
Confirmed intracranial objective response
No. of patients 29 8
% (95% CI) 67 (51–81) 17 (8–31) 13.00 (4.38–38.61)
Intracranial complete response — no. (%) 16 (37) 2 (4)
Intracranial partial response — no. (%) 13 (30) 6 (13)
Rate of intracranial objective response at ≥1 assessment — % (95% CI) 79 (64–90) 23 (12–38) 16.30 (5.32–49.92)
Intracranial complete response — no. (%) 19 (44) 4 (9)
Intracranial partial response — no. (%) 15 (35) 7 (15)
*  NR denotes not reached.
†  Measurable brain metastases were at least 10 mm in diameter.
Table 2. Rates of Systemic and Intracranial Objective Response, Assessed by Blinded Independent Review.*
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progression, alone or with concurrent systemic 
progression. In patients without brain metastases 
at baseline, 1% (1 of 94 patients) in the brigatinib 
group and 5% (5 of 91 patients) in the crizotinib 
group had intracranial disease progression as 
the first site of disease progression.
The estimated rate of 12-month survival with-
out intracranial disease progression among pa-
tients with baseline brain metastases was 67% 
(95% CI, 47 to 80) in the brigatinib group and 
21% (95% CI, 6 to 42) in the crizotinib group; 
the estimated rate of 12-month survival without 
intracranial disease progression in the intention-
to-treat population was 78% (95% CI, 68 to 85) 
in the brigatinib group and 61% (95% CI, 50 to 
71) in the crizotinib group. The rate of survival 
without intracranial disease progression among 
patients with baseline brain metastases was 
higher in the brigatinib group than in the crizo-
tinib group (hazard ratio for intracranial disease 
progression or death, 0.27; 95% CI, 0.13 to 0.54) 
(Fig. 2D), and the rate of survival without intra-
cranial disease progression among patients in 
the intention-to-treat population was higher in 
the brigatinib group than in the crizotinib group 
(hazard ratio, 0.42; 95% CI, 0.24 to 0.70). An 
exploratory competing-risks analysis of intracra-
nial disease progression, systemic progression, 
and death in the intention-to-treat population 
showed that the cause-specific hazard ratio for 
time to progression of intracranial disease was 
0.30 (95% CI, 0.15 to 0.60) (Fig. S3 in the Sup-
plementary Appendix).
At data cutoff, 34 patients in the intention-to-
treat population had died (17 patients in the 
brigatinib group [12%] and 17 patients in the 
crizotinib group [12%]). The 1-year rate of over-
all survival was 85% (95% CI, 76 to 91) with 
brigatinib and 86% (95% CI, 77 to 91) with 
crizotinib (Fig. S4 in the Supplementary Appen-
dix). The median overall survival was not reached 
in either group.
Safety
The most common (>25% of patients overall) 
adverse events of any grade that occurred during 
treatment were gastrointestinal symptoms, in-
creased blood creatine kinase levels, and in-
creased alanine aminotransferase levels (Table 3, 
and Table S2 in the Supplementary Appendix). 
Adverse events that occurred at a higher incidence 
by more than 5 percentage points with brigatinib 
than with crizotinib included an increased cre-
atine kinase level (brigatinib [39%] vs. crizotinib 
[15%]), cough (25% vs. 16%), hypertension (23% 
vs. 7%), and an increased lipase level (19% vs. 
12%). Adverse events that were more common 
with crizotinib than with brigatinib included 
nausea (crizotinib [56%] vs. brigatinib [26%]), 
diarrhea (55% vs. 49%), constipation (42% vs. 
15%), peripheral edema (39% vs. 4%), vomiting 
(39% vs. 18%), an increased alanine aminotrans-
ferase level (32% vs. 19%), decreased appetite 
(20% vs. 7%), photopsia (20% vs. 1%), dysgeusia 
(19% vs. 4%), and visual impairment (16% vs. 
0%). Grade 3 to 5 adverse events occurred in 
61% of patients in the brigatinib group and in 
55% of patients in the crizotinib group. No 
cases of pancreatitis were reported. Symptoms 
possibly related to increased creatine kinase levels 
(myalgia and muscle pain) did not differ sub-
stantially between the groups, nor were they ap-
parently related to the grade of increased creatine 
kinase levels (Table 3).
Fourteen patients had adverse events leading 
to death within 30 days after the last dose of 
the trial drug (7 [5%] in the brigatinib group and 
7 [5%] in the crizotinib group); none of the 
events were deemed by the investigators to be 
related to trial treatment. Interstitial lung dis-
ease or pneumonitis at any time occurred in 4% 
(5 of 136) of patients in the brigatinib group and 
2% (3 of 137) of patients in the crizotinib group. 
Grade 3 or 4 interstitial lung disease or pneumo-
nitis occurred in 3% (4 of 136) and 0.7% (1 of 
137), respectively. Interstitial lung disease or pneu-
monitis of any grade with early onset (defined as 
occurring within 14 days after the initiation of 
treatment) was observed in 4 of 136 patients 
(3%) in the brigatinib group (onset on days 3 to 
8) and was not observed in patients who received 
crizotinib. All 4 patients discontinued brigatinib 
after the pulmonary event, according to the pro-
tocol. Among patients who crossed over from 
crizotinib to brigatinib, the rate of interstitial 
lung disease or pneumonitis of any grade was 
3% (1 of 35 patients), and it occurred on day 3.
An investigator- or protocol-mandated dose 
reduction for any adverse events occurred in 
29% of treated patients in the brigatinib group 
and 21% of treated patients in the crizotinib 
group. The most common adverse events leading 
to dose reduction are shown in Table S3 in the 
Supplementary Appendix. A total of 12% of pa-
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tients who received brigatinib and 9% of patients 
who received crizotinib discontinued treatment 
owing to adverse events.
Discussion
In ALTA-1L, brigatinib, as compared with crizo-
tinib, had superior efficacy against systemic and 
intracranial disease. At the first interim analysis, 
the prespecified threshold for significance for 
the primary end point of blinded independent 
review–assessed progression-free survival with 
brigatinib was met. With a median follow-up 
of 11.0 months in the brigatinib group and 9.3 
months in the crizotinib group, brigatinib was 
associated with a 51% lower risk of disease pro-
Event Brigatinib (N = 136) Crizotinib (N = 137)
Any Grade Grade ≥3 Any Grade Grade ≥3
number of patients (percent)
Any adverse event 132 (97) 83 (61) 137 (100) 76 (55)
Diarrhea 67 (49) 2 (1) 75 (55) 3 (2)
Increased blood creatine kinase level* 53 (39) 22 (16) 21 (15) 2 (1)
Nausea 36 (26) 2 (1) 77 (56) 4 (3)
Cough 34 (25) 0 22 (16) 0
Hypertension 31 (23) 13 (10) 10 (7) 4 (3)
Increased alanine aminotransferase level 26 (19) 2 (1) 44 (32) 13 (9)
Increased lipase level† 26 (19) 18 (13) 16 (12) 7 (5)
Vomiting 25 (18) 1 (1) 54 (39) 3 (2)
Constipation 20 (15) 0 57 (42) 1 (1)
Increased amylase level† 19 (14) 7 (5) 9 (7) 1 (1)
Pruritus 18 (13) 1 (1) 6 (4) 1 (1)
Rash 14 (10) 0 3 (2) 0
Decreased appetite 10 (7) 1 (1) 27 (20) 4 (3)
Dermatitis acneiform 9 (7) 0 2 (1) 0
Dyspepsia 8 (6) 0 18 (13) 0
Epistaxis 8 (6) 0 0 0
Bradycardia 7 (5) 1 (1) 17 (12) 0
Peripheral edema 6 (4) 1 (1) 53 (39) 1 (1)
Dysgeusia 6 (4) 0 26 (19) 0
Upper abdominal pain 6 (4) 1 (1) 18 (13) 2 (1)
Pain in extremity 6 (4) 0 17 (12) 1 (1)
Increased blood creatinine level 3 (2) 0 19 (14) 1 (1)
Neutropenia 2 (1) 0 12 (9) 6 (4)
Pleural effusion 2 (1) 1 (1) 9 (7) 2 (1)
Photopsia 1 (1) 0 28 (20) 1 (1)
Gastroesophageal reflux disease 1 (1) 0 12 (9) 0
Visual impairment 0 0 22 (16) 0
Deep-vein thrombosis 0 0 8 (6) 0
*  Myalgia was reported in 6% of patients in the brigatinib group and 4% of patients in the crizotinib group; musculoskeletal pain was report-
ed in 4% and 6% of the patients, respectively. No myalgia or musculoskeletal pain of grade 3 or greater was reported in either group.
†  No clinical cases of pancreatitis were reported in either group.
Table 3. Adverse Events of Any Grade That Differed by More Than 5 Percentage Points in Frequency between Groups.
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gression or death than crizotinib (hazard ratio, 
0.49; P<0.001). The rate of progression-free sur-
vival at 12 months was 67% in the brigatinib 
group (median not reached) and 43% in the crizo-
tinib group (median, 9.8 months, consistent with 
results seen in other randomized trials).4,27
The hazard ratio for disease progression or 
death was 0.55 (95% CI, 0.34 to 0.88) among 
patients who had not received chemotherapy and 
0.35 (95% CI, 0.14 to 0.85) among those who 
had received previous chemotherapy. One of the 
lowest hazard ratios for disease progression or 
death was noted among patients with baseline 
brain metastases (0.20; 95% CI, 0.09 to 0.46). 
Although the hazard ratio for disease progres-
sion or death did not reach significance among 
patients without baseline brain metastases (0.72; 
95% CI, 0.44 to 1.18), this interim analysis may 
emphasize differences in early progression. Be-
cause of the known poor efficacy of crizotinib in 
the CNS, CNS progression events may tend to 
have an earlier onset than other events; there-
fore, differences in early progression-free sur-
vival will be most apparent among patients with 
baseline brain disease.
Randomized, phase 3 trial data show that 
treatment options for patients with advanced 
NSCLC who have not previously received ALK 
inhibitors include crizotinib, alectinib, and ceri-
tinib.4,27,28 Despite shorter follow-up, these initial 
results for brigatinib as compared with crizo-
tinib in patients who had not previously received 
ALK inhibitors appear similar to results from the 
phase 3 BO28984 (ALEX) trial, which compared 
alectinib, a second-generation ALK inhibitor, with 
crizotinib. Both the rates of progression-free 
survival and overall response were similar in the 
crizotinib groups in both trials.27 Previous che-
motherapy was not permitted in the ALEX trial 
as it was in ALTA-1L, and ALK status was cen-
trally confirmed by Ventana immunohistochem-
ical analysis.27 Crossover from crizotinib at pro-
gression was not permitted in the ALEX trial27 as 
it was in ALTA-1L.
The primary end point of the ALEX trial was 
investigator-assessed progression-free survival. 
Analysis by an independent review committee 
was conducted only at the primary analysis time 
point.27,29 Investigator-assessed progression-free 
survival with a median follow-up of 17.6 to 18.6 
months was associated with 12-month event-free 
survival rates of 68.4% (95% CI, 61.0 to 75.9) in 
the alectinib group and 48.7% (95% CI, 40.4 to 
56.9) in the crizotinib group (hazard ratio, 0.47; 
95% CI, 0.34 to 0.65; P<0.001), with no median 
reached in the alectinib group. The analysis of 
the independent review committee showed me-
dian progression-free survival of 25.7 months 
(95% CI, 19.9 to could not be estimated) in the 
alectinib group and 10.4 months (95% CI, 7.7 to 
14.6) in the crizotinib group (hazard ratio, 0.53; 
95% CI, 0.38 to 0.73; P<0.001).27,30 A post hoc 
analysis with an additional 10 months of follow-
up showed investigator-assessed median progres-
sion-free survival of 34.8 months among pa-
tients in the alectinib group (hazard ratio, 0.43; 
95% CI, 0.32 to 0.58); this shows that efficacy in 
these patients can improve over time because of 
the greater emergence of plateaus in the Kaplan–
Meier curve in the experimental group than in 
the control group.29
The safety profiles of brigatinib and crizotinib 
were consistent with those in previous stud-
ies.4,16,27,31 Elevated creatine kinase levels were not 
associated with the frequency or severity of my-
algia or musculoskeletal pain, and there were no 
cases of clinical pancreatitis. The rate of dose 
reduction because of any adverse events was 29% 
in the brigatinib group and 21% in the crizotinib 
group, in part reflecting more stringent protocol-
mandated dose modifications for laboratory ab-
normalities with brigatinib as compared with 
crizotinib modifications, which followed stan-
dard labeling (Table S3 in the Supplementary 
Appendix, and the trial protocol). Early-onset 
pulmonary events (interstitial lung disease and 
pneumonitis) were observed with brigatinib but 
not crizotinib. The rate of these events with 
brigatinib among patients who had not previ-
ously received ALK inhibitors (3%) appears to be 
lower than among patients with disease that was 
refractory to crizotinib (6% in ALTA),16 despite 
similar drug exposures (Fig. S5 in the Supple-
mentary Appendix). Consistent with a multivari-
ate analysis indicating that a longer washout 
period (≥7 days) from crizotinib reduced the risk 
of these events,16 the rate of early-onset pulmo-
nary events among patients who crossed over 
from crizotinib to brigatinib (3%), which required 
a 10-day minimum washout period, appeared to 
be lower than the rate observed in ALTA.
A key strength of this open-label trial is that 
progression-free survival was assessed by a blind-
ed independent review committee, minimizing 
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the potential for bias associated with investigator 
assessments. In addition, ALK positivity defined 
with the use of real-world assays was incorpo-
rated, potentially increasing the applicability of 
these data, and patients could have received previ-
ous chemotherapy. A limitation of this analysis 
is that overall survival data will be confounded 
by crossover of patients in the crizotinib group 
to brigatinib during the trial and subsequent use 
of other tyrosine kinase inhibitors after discon-
tinuation of the trial by patients from either 
group. With further follow-up, data in both 
groups will mature and help to better contextu-
alize the role of brigatinib as compared with 
other next-generation ALK inhibitors.
In conclusion, among patients with ALK-posi-
tive NSCLC who had not previously received an 
ALK inhibitor, progression-free survival was 
significantly longer among those who received 
brigatinib than among those who received crizo-
tinib.
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